VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 763 filers reported holding VANECK VECTORS ETF TR in Q1 2022. The put-call ratio across all filers is 0.66 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $45,680,183 | +14.0% | 1,697,517 | +27.5% | 0.86% | +9.1% |
Q2 2023 | $40,077,463 | +110890.2% | 1,331,035 | +5.6% | 0.79% | +33.8% |
Q4 2022 | $36,109 | -99.9% | 1,259,917 | -39.5% | 0.59% | -34.5% |
Q3 2022 | $50,194,000 | +48.8% | 2,080,989 | +68.9% | 0.90% | +86.9% |
Q2 2022 | $33,732,000 | +13.4% | 1,231,993 | +58.8% | 0.48% | -2.6% |
Q1 2022 | $29,755,000 | -39.3% | 775,886 | -52.2% | 0.49% | -44.6% |
Q4 2021 | $49,029,000 | +394.7% | 1,621,838 | +382.3% | 0.89% | +354.6% |
Q3 2021 | $9,910,000 | -48.8% | 336,272 | -40.9% | 0.20% | -44.5% |
Q2 2021 | $19,347,000 | -80.4% | 569,360 | -81.3% | 0.35% | -80.2% |
Q1 2021 | $98,769,000 | -47.0% | 3,039,060 | -41.2% | 1.79% | -46.9% |
Q4 2020 | $186,219,000 | +19.2% | 5,169,893 | +29.6% | 3.37% | +34.5% |
Q3 2020 | $156,162,000 | +16.5% | 3,987,794 | +9.1% | 2.50% | +20.3% |
Q2 2020 | $134,100,000 | +0.6% | 3,655,941 | -36.8% | 2.08% | -10.5% |
Q1 2020 | $133,266,000 | – | 5,784,123 | – | 2.33% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |